Lung adenocarcinoma in a patient with a cis EGFR L858R‐K860I doublet mutation identified using NGS‐based profiling test: Negative diagnosis on initial companion test and successful treatment with osimertinib

Tyrosine kinase inhibitors are used as first‐line treatment for non‐small cell lung cancer (NSCLC) patients harboring driver mutations in EGFR, ALK, ROS1, and BRAF. Currently, standard molecular testing approaches help identify single genes for such targetable driver mutations in NSCLC; however, nex...

Descripción completa

Detalles Bibliográficos
Autores principales: Onozawa, Hiroto, Saito, Haruhiro, Sunami, Kuniko, Kubo, Takashi, Yamamoto, Noboru, Kasajima, Rika, Ohtsu, Takashi, Hiroshima, Yukihiko, Kanamori, Heiwa, Yokose, Tomoyuki, Miyagi, Yohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705914/
https://www.ncbi.nlm.nih.gov/pubmed/33034420
http://dx.doi.org/10.1111/1759-7714.13694

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7705914/
https://www.ncbi.nlm.nih.gov/pubmed/33034420
http://dx.doi.org/10.1111/1759-7714.13694

Ejemplares similares